Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-08-08
2010-02-16
Kosar, Andrew D (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S317000
Reexamination Certificate
active
07662779
ABSTRACT:
The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters or prodrugs thereof:which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering to the subject a pharmaceutical composition comprising a compound of the present invention.
REFERENCES:
patent: 6608027 (2003-08-01), Tsantrizos et al.
patent: 7173004 (2007-02-01), McPhee et al.
patent: 7176208 (2007-02-01), Nakajima et al.
patent: 2005/0119168 (2005-06-01), Venkatraman et al.
patent: 2005/0153877 (2005-07-01), Miao et al.
patent: 2005/0153900 (2005-07-01), Velazquez et al.
patent: 2005/0164921 (2005-07-01), Njoroge et al.
patent: 2007/0060510 (2007-03-01), Nakajima et al.
patent: 2007/0099825 (2007-05-01), D'Andrea et al.
patent: 2008/0038225 (2008-02-01), Sun et al.
Tsantrizos et al, “Macrocyclic Inhibitors of the NS3 Protease as Potential Therapeutic Agents of Hepatitis C Virus Infection,” Angew. Chem. Int. Ed. (2003), vol. 42, pp. 1356-1360.
R.C. Griffith et al., “HCV Anti-viral Agents”, Annual Reports in Medicinal Chemistry, vol. 39, p. 223-237. (2004 Elsevier Inc.).
U.S. Appl. No. 11/832,240, filed Aug. 1, 2007, Sun et al.
U.S. Appl. No. 11/832,893, filed Aug. 4, 2007, Moore et al.
U.S. Appl. No. 11/835,157, filed Aug. 7, 2007, Sun et al.
Niu Deqiang
Or Yat Sun
Sun Ying
Wang Zhe
Elmore Carolyn S.
Elmore Patent Law Group P.C.
Enanta Pharmaceuticals, Inc.
Harlan Edgar W.
Kosar Andrew D
LandOfFree
Triazolyl macrocyclic hepatitis C serine protease inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Triazolyl macrocyclic hepatitis C serine protease inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Triazolyl macrocyclic hepatitis C serine protease inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4170778